CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 58 enrolled
Drug / intervention
Levetiracetam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03875638
NCT03875638Phase 2Completed
CompareCT.gov

Treating Hyperexcitability in Alzheimer's Disease With Levetiracetam to Improve Brain Function and Cognition

Beth Israel Deaconess Medical Center·interventional·Posted Mar 15, 2019·Updated Apr 7, 2026

In Brief

A Phase 2 clinical trial evaluating Levetiracetam and Placebo oral capsule for Alzheimer Dementia and 3 related conditions. Completed, enrolled 58 participants across 1 site.

Detailed Summary

The aim of this study is to explore the relationship between cortical hyperexcitability, abnormalities of brain network function, and cognitive dysfunction in human patients with AD and whether administration of the antiepileptic medication levetiracetam (LEV) normalizes these measures and improves cognition.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 15, 2019
Enrollment StartAug 22, 2019
Primary CompletionFeb 16, 2026
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 7.3 years ago

Interventions

Levetiracetamdrug

Levetiracetam is an antiepileptic medication that has been shown to reduced network cortical hyperexcitability

Placebo oral capsuledrug

The placebo is a capsule that is identical in appearance to the levetiracetam